Philip Rosenstrach‘s Pomelo Capital is a New York-based investment fund that started its operations in 2012 after spinning off from Barclays’s capital arbitrage arm. The fund’s equity portfolio was valued at $2.17 billion at the end of September, compared to $1.97 billion at the end of the second quarter. Pomelo Capital’s long positions in companies worth at least $1.0 billion generated a weighted average return of 18.5% during the third quarter and it was ranked the 35th best performing hedge fund in our database. Hedge funds on average underperform the market in bull markets because they are hedged. In our rankings, we consider only their long positions in companies worth at least $1.0 billion. This way when we can compare these returns to the returns of the S&P 500 ETFs – which are basically 100% long portfolios of large-cap stocks – it is a straightforward apples-to-apples comparison.
Our approach reveals interesting facts about hedge funds’ stock picking skills. For instance, there were 659 hedge funds in our database that had at least 5 non-microcap stocks in their 13F portfolio. These hedge funds’ long portfolio managed to deliver an average return of 8.3% during the third quarter whereas S&P 500 ETFs returned only 3.3%. We should note that hedge fund investors didn’t see average gains of 8.3% in their statements for two reasons. First, most hedge funds are hedged. This means they make 8% on the long side of their portfolio but they lose money on the short side of their portfolio. Their net returns also shrink after taking into account their cash or debt positions that don’t usually return much in this environment. Second, we don’t like this and believe that hedge fund fees are excessive, most hedge funds charge an arm and a leg for their services. Net of hedging and fees, it isn’t surprising to see that hedge fund investors experience lower returns than index fund investors. If investors don’t want the downside protection that comes with investing in hedge funds and want to beat the market returns, they can consider investing in the individual stock picks successful hedge fund managers.
That’s why we will be looking at the stock picks of Pomelo Capital in this article.
Pomelo Capital had initiated a stake in American Airlines Group Inc (NASDAQ:AAL) during the second quarter, buying 527,000 shares of the company worth over $14.92 million at the end of June. However, in the third quarter, amid a 29.7% advance registered by the company’s stock, the fund cut the position by 57% to 224,800 shares worth $8.23 million at the end of September. Overall, American Airlines Group Inc (NASDAQ:AAL) saw 56 funds from our database holding shares at the end of June, down from 61 funds a quarter earlier. Among these funds, Adage Capital Management held the most valuable stake in American Airlines Group Inc (NASDAQ:AAL), which was worth $178.2 million at the end of the second quarter. On the second spot was Stelliam Investment Management which amassed $174 million worth of shares. Moreover, Masters Capital Management, Cyrus Capital Partners, and Highland Capital Management were also bullish on American Airlines Group Inc (NASDAQ:AAL).
Follow American Airlines Group Inc. (NASDAQ:AAL)
Follow American Airlines Group Inc. (NASDAQ:AAL)
Pomelo had upped its stake in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) by 68% in the second quarter, ending the period with a total of 724,900 shares of the company. In the third quarter, the stock appreciated by 21.9% and as the fund left the stake unchanged, its value went up to $17.80 million from $14.60 million. At the end of the second quarter, a total of 60 of the hedge funds tracked by Insider Monkey were long this stock, down by 15% from the previous quarter. Among these funds, Pershing Square held the most valuable stake in Valeant Pharmaceuticals Intl Inc (NYSE:VRX), which was worth $434.8 million at the end of the second quarter. On the second spot was Paulson & Co which amassed $384.1 million worth of shares. Moreover, ValueAct Capital, Okumus Fund Management, and Pentwater Capital Management were also bullish on Valeant Pharmaceuticals Intl Inc (NYSE:VRX).
